Vinge advises Xspray Pharma AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm. The prospectus was published on 23 March 2020 and the trading on Nasdaq Stockholm commenced on 27 March 2020.
Vinge has advised the pharmaceutical development company Cinclus Pharma in connection with a capital raising of approximately SEK 250 million by way of a directed share issue to several new investors and current shareholders.
With the close of the transaction, 100% of the shares in the wholly owned Sye business subsidiary, all relevant IPRs and contracts and about 30 employees and consultants have been transferred to the acquirer.
Vinge has advised Industrifonden and Investinor in connection with a sale of in total approximately 2,300,000 shares in Calliditas Therapeutics AB (publ) to two investors for a total value of approximately USD 17,000,000.
Vinge has advised Azelio AB (publ) on a fully subscribed rights issue, which will provide Azelio with issue proceeds amounting to approximately SEK 350 million before deduction of transaction costs.
Vinge has advised AMF and Folksam in connection with their SEK 5 bn reinvestment in Volvo Cars in connection with the redemption of existing preference shares.
Vinge has advised the risk and compliance software company NAVEX Global in connection with its acquisition of WhistleB Whistleblowing Centre AB, a company which offers an integrated whistleblowing case management system with reporting options in over 60 languages used by customers in more than 150 countries.
Vinge has advised the pharmaceutical development company Xspray Pharma in connection with a directed share issue, whereby Xspray receives proceeds of approximately SEK 122 million.
Vinge advised Nordea Bank Abp and Citigroup Global Markets Limited which are acting as Global Coordinators and Bookrunners in connection with a directed share issue of SEK 312 million in Better Collective A/S through an accelerated book building procedure.
